Biotech

Shift Bioscience Unveils Breakthrough Single-Gene Target for Safe Cellular Rejuvenation

SB000 reverses cellular aging across multiple cell types without triggering risky pluripotency pathways.

PeproMene Bio Reports Complete Remission in First Follicular Lymphoma Patient from Phase 1 Trial

BAFFR-targeted CAR T cell therapy shows promise in treating relapsed follicular lymphoma.

Using Jumping Genes for Safer, More Accurate DNA Editing

Researchers have developed a new gene-editing technique called bridge editing, which uses bacterial "jumping genes" to precisely insert large DNA sequences into the human genome without causing harmful DNA breaks, offering a safer and more efficient method for treating genetic disorders.

FDA Clears Blood Test for Diagnosing Alzheimer’s Disease

The FDA has approved a new plasma-based biomarker assay, the first blood-based diagnostic for Alzheimer's disease, offering a less invasive and more accessible alternative to traditional methods like PET scans and spinal taps.

Cerevance Reports Phase 2 Results for Solengepras in Early-Stage Parkinson’s Disease

Cerevance has announced topline results from its Phase 2 ASCEND trial of solengepras, showing a small but non-significant improvement in motor symptoms and potential benefits for non-motor symptoms, with a strong safety profile.

AstraZeneca to Acquire EsoBiotec in $1B Deal to Drive Next-Generation Cell Therapy

AstraZeneca announces acquisition of EsoBiotec for $1 billion, aiming to advance its cell therapy capabilities with EsoBiotec's in vivo genetic programming platform for cancer and immune-mediated diseases.